Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.
暂无分享,去创建一个
C. Taylor | M. Knowles | P. Selby | R. Banks | N. Hornigold | A. Joyce | E. Maher | A. Stanley | P. Harnden | D. Astuti | P. Tirukonda | Dena Cohen | Claire F. Taylor
[1] Kentaro Takahashi,et al. [Von Hippel-Lindau disease]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.
[2] Ya‐Wen Cheng,et al. Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non‐small cell lung cancer , 2005, International journal of cancer.
[3] F. Marshall. Promoter hypermethylation profile of kidney cancer. , 2005, The Journal of urology.
[4] E. Voest,et al. Tumor Suppression by the von Hippel-Lindau Protein Requires Phosphorylation of the Acidic Domain* , 2005, Journal of Biological Chemistry.
[5] P. A. van den Brandt,et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from the Netherlands cohort study , 2005, BMC Cancer.
[6] J. Kim,et al. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma , 2005 .
[7] J. Halgunset,et al. Low copy number DNA template can render polymerase chain reaction error prone in a sequence-dependent manner. , 2005, The Journal of molecular diagnostics : JMD.
[8] W. Kaelin,et al. Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. Junien,et al. Genotype–phenotype correlation in von Hippel‐Lindau families with renal lesions , 2004, Human mutation.
[10] W. Krek,et al. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. , 2004, Trends in molecular medicine.
[11] M. Guo,et al. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation. , 2004, Cancer genetics and cytogenetics.
[12] H. Brauch,et al. VHL mutations in renal cell cancer: does occupational exposure to trichloroethylene make a difference? , 2004, Toxicology letters.
[13] M. Urioste,et al. Genetic characterization and structural analysis of VHL Spanish families to define genotype–phenotype correlations , 2004, Human mutation.
[14] J. Decaprio,et al. Molecular cloning and characterization of the von Hippel-Lindau-like protein. , 2004, Molecular cancer research : MCR.
[15] E. Messing,et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. , 2003, The Journal of urology.
[16] M. Hughson,et al. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene. , 2003, Cancer genetics and cytogenetics.
[17] T. Shuin,et al. Molecular detection of von Hippel-Lindau gene mutations in urine and lymph node samples in patients with renal cell carcinoma: potential biomarkers for early diagnosis and postoperative metastatic status. , 2003, The Journal of urology.
[18] Kazuki Kobayashi,et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.
[19] T. Shuin,et al. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma , 2002, Journal of Cancer Research and Clinical Oncology.
[20] H. Ishida,et al. Vascular endothelial growth factor overexpression is correlated with von Hippel‐Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma , 2002, Cancer.
[21] M. Seyfarth,et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. , 2002, Blood.
[22] T. Shuin,et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathological parameters , 2002, Genes, chromosomes & cancer.
[23] M. Amin,et al. Mutations in the von Hippel‐Lindau (VHL) gene refine differential diagnostic criteria in renal cell carcinoma , 2002, Journal of surgical oncology.
[24] M. Shin,et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[25] Holger Moch,et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.
[26] M. Esumi,et al. Biallelic inactivation of the von Hippel-Lindau tumor suppressor gene in sporadic renal cell carcinoma. , 2002, The Journal of urology.
[27] 蘆田 真吾. Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma , 2002 .
[28] Xin Ma,et al. VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium , 2001, Oncogene.
[29] C. Junien,et al. Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma. , 2001, Pharmacogenetics.
[30] S. Antonarakis,et al. Nomenclature for the description of human sequence variations , 2001, Human Genetics.
[31] S. Nakamura,et al. Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] P. Wernet,et al. Novel mutations of the von Hippel‐Lindau tumor‐suppressor gene and rare DNA hypermethylation in renal‐cell carcinoma cell lines of the clear‐cell type , 2000, International journal of cancer.
[33] P. Schirmacher,et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. , 2000, Cancer research.
[34] F. Pontén,et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. , 1999, The American journal of pathology.
[35] J. Brieger,et al. Detection of a novel germline mutation in the von Hippel–Lindau tumour‐suppressor gene by fluorescence‐labelled base excision sequence scanning (F‐BESS) , 1999, Clinical genetics.
[36] K. Hemminki,et al. Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas. , 1999, Cancer letters.
[37] H. Brauch,et al. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. , 1999, Journal of the National Cancer Institute.
[38] A. Hattersley,et al. Loss of HNF1α function in human renal cell carcinoma: Frequent mutations in the VHL gene but not the HNF1α gene , 1999, Molecular carcinogenesis.
[39] C. Junien,et al. Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC , 1999, Human mutation.
[40] S. Clifford,et al. Inactivation of the von Hippel–Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: Evidence for a VHL‐independent pathway in clear cell renal tumourigenesis , 1998 .
[41] S. Clifford,et al. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. , 1998, Genes, chromosomes & cancer.
[42] H. Ito,et al. Mutational state of von Hippel-Lindau and adenomatous polyposis coli genes in renal tumors. , 1997, Oncology.
[43] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[44] W. Linehan,et al. Detection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimens. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[45] P. Bugert,et al. MUTATION OF THE VHL GENE IS ASSOCIATED EXCLUSIVELY WITH THE DEVELOPMENT OF NON‐PAPILLARY RENAL CELL CARCINOMAS , 1996, The Journal of pathology.
[46] C. Bain,et al. Somatic mutations of von Hippel‐Lindau (VHL) tumor‐suppressor gene in european kidney cancers , 1995, International journal of cancer.
[47] M. Ferguson-Smith,et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.
[48] B. Seizinger,et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. , 1994, American journal of human genetics.
[49] J. Herman,et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[50] Y Kubota,et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.
[51] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[52] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.